GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan
· Delayed Price · Currency is TWD 19.80
-0.15 (-0.75%)
May 9, 2025, 1:30 PM CST
GeneReach Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -118.73 | -166.27 | 221.34 | 376.62 | 257.28 | Upgrade
|
| Depreciation & Amortization | 74.73 | 68.03 | 64.28 | 59.24 | 51.33 | Upgrade
|
| Other Amortization | - | 0.86 | 0.89 | 0.77 | 0.5 | Upgrade
|
| Loss (Gain) From Sale of Assets | 28.17 | 1.39 | -1.7 | -0.41 | -0.5 | Upgrade
|
| Loss (Gain) From Sale of Investments | 2.57 | 2.5 | 3.7 | 3.81 | 5.19 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | 0.04 | Upgrade
|
| Provision & Write-off of Bad Debts | -4.65 | 21.43 | -1.13 | 5.06 | 1.99 | Upgrade
|
| Other Operating Activities | -1.35 | -66.17 | -65.61 | 14.8 | 58.93 | Upgrade
|
| Change in Accounts Receivable | -16.97 | 12.04 | 138.08 | -31.15 | -93.49 | Upgrade
|
| Change in Inventory | 14.8 | 124.59 | 16.07 | -91.29 | -156.1 | Upgrade
|
| Change in Accounts Payable | 2.76 | -0.24 | -6.04 | -5.44 | 4.55 | Upgrade
|
| Change in Unearned Revenue | -0.55 | -2.84 | -11.49 | 13.17 | - | Upgrade
|
| Change in Other Net Operating Assets | -4 | -33.99 | -0.73 | 3.82 | 40.1 | Upgrade
|
| Operating Cash Flow | -23.22 | -38.67 | 357.63 | 348.99 | 169.82 | Upgrade
|
| Operating Cash Flow Growth | - | - | 2.48% | 105.51% | - | Upgrade
|
| Capital Expenditures | -7.12 | -23.53 | -49.87 | -19.56 | -62.2 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.17 | - | 3.93 | 1.97 | 0.82 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.34 | -3.82 | -0.59 | -1.36 | -2.67 | Upgrade
|
| Investment in Securities | -62.75 | -221.54 | - | 3.85 | - | Upgrade
|
| Other Investing Activities | 0.84 | -1.02 | -1.48 | -26.61 | -44.85 | Upgrade
|
| Investing Cash Flow | -70.21 | -249.91 | -48.01 | -41.7 | -108.9 | Upgrade
|
| Short-Term Debt Issued | 137 | 55 | - | - | 51 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 198 | 30 | Upgrade
|
| Total Debt Issued | 137 | 55 | - | 198 | 81 | Upgrade
|
| Short-Term Debt Repaid | -70 | - | - | -2 | - | Upgrade
|
| Long-Term Debt Repaid | -47.58 | -201.94 | -19.35 | -8.82 | -5.95 | Upgrade
|
| Total Debt Repaid | -117.58 | -201.94 | -19.35 | -10.82 | -5.95 | Upgrade
|
| Net Debt Issued (Repaid) | 19.42 | -146.94 | -19.35 | 187.18 | 75.05 | Upgrade
|
| Common Dividends Paid | - | -68.95 | -208.94 | -143.67 | - | Upgrade
|
| Other Financing Activities | -15.99 | - | - | -0.04 | - | Upgrade
|
| Financing Cash Flow | 3.43 | -215.89 | -228.28 | 43.48 | 75.05 | Upgrade
|
| Foreign Exchange Rate Adjustments | -16.5 | -27.37 | 3.84 | -1.01 | 0.69 | Upgrade
|
| Net Cash Flow | -106.5 | -531.84 | 85.18 | 349.75 | 136.66 | Upgrade
|
| Free Cash Flow | -30.35 | -62.21 | 307.76 | 329.43 | 107.62 | Upgrade
|
| Free Cash Flow Growth | - | - | -6.58% | 206.11% | - | Upgrade
|
| Free Cash Flow Margin | -14.70% | -27.59% | 41.03% | 32.55% | 12.56% | Upgrade
|
| Free Cash Flow Per Share | -0.53 | -1.08 | 5.19 | 5.62 | 1.87 | Upgrade
|
| Cash Interest Paid | 5.54 | 4.56 | 4.58 | 5.26 | 3.82 | Upgrade
|
| Cash Income Tax Paid | 5.4 | 14.03 | 117.39 | 78.3 | 21.84 | Upgrade
|
| Levered Free Cash Flow | 21.04 | 22.55 | 262.91 | 331.25 | 46.48 | Upgrade
|
| Unlevered Free Cash Flow | 24.75 | 26.15 | 267.04 | 335.16 | 48.86 | Upgrade
|
| Change in Net Working Capital | -40.49 | -127.92 | -101.5 | 5.4 | 160.23 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.